All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The AML Global Portal were delighted to speak to Liran Shlush, Weizmann Institute of Science, Rehovot, IL, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Liran Shlush: Can genetic testing predict AML risk in healthy individuals?
Liran Shlush discusses the current methods being developed to predict AML such as blood tests and molecular testing (Deep sequencing of targeted genes), which will possibly enable identification of healthy individual at high risk of developing AML by using a mathematical model. Liran Shlush explains the future implication of clinical trials being designed to enrol healthy, high-risk individuals to receive preventative therapy.
Can genetic testing predict AML risk in healthy individuals?
Subscribe to get the best content related to AML delivered to your inbox